Hasifah Namatovu Kasujja
ID:
|
eHealth Adoption in Uganda. What is the status? eHAU
REFNo: SS945ES
1. To inventory existing eHealth interventions in Uganda to ascertain maturity, failure and successes
2. To study the barriers and facilitators of eHealth adoption in Uganda
3. To develop a framework for successful eHealth adoption
4. To evaluate the framework for utility
|
Uganda |
2021-08-23 |
2024-08-23 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Ronald Kiguba
ID: UNCST-2019-R000844
|
Two-way risk communication mobile application use versus traditional methods of adverse drug reaction reporting in Uganda: a cluster-randomized controlled trial
REFNo: HS1366ES
This study will: i) assess the feasibility of implementing a mobile app for the reporting of ADRs associated with DTG and IPT at selected ART-sites in Uganda; ii) describe the characteristics (causality, seriousness, completeness, unexpectedness, severity, outcome) of the DTG- and IPT-linked ADR-reports submitted to NPC using the mobile app; and, iii) determine if use of the mobile app versus existing methods of ADR-reporting (paper-form and web-form) increases by 25% the number of reported ADRs linked to DTG and IPT use during 2.5 years of follow-up, iv) determine the cost and cost-effectiveness of using the mobile app versus existing methods of ADR-reporting.
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in
Regions with SARS-CoV-2 Variants of Concern.
REFNo: HS1669ES
-To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent
virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in
adults who are at risk of severe COVID-19
-2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
-3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Philippa Musoke
ID: UNCST-2021-R013523
|
ViiV 205858: Open-label access to dolutegravir for HIV-1 infected children
and adolescents completing IMPAACT Studies P1093 and P2019 Version 4.0 dated 10 Dec 2020
REFNo: HS1453ES
Primary
• To provide access to age appropriate formulations of dolutegravir (DTG), either as single entity DTG or as fixed dose combination (FDC) abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), in an open-label protocol to eligible participant s who have completed the P1093 or P2019 parent studies.
Secondary
To assess any serious adverse events (SAEs) and any clinical or laboratory adverse events that lead to the discontinuation of IP (DTG or ABC/DTG/3TC FDC).
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Baker Lukwago
ID: UNCST-2021-R013259
|
Tracking DISC project activities through integrated surveys in Uganda_Version One May 2021
REFNo: HS1481ES
This research protocol includes the DISC research that will happen from 2021 to 2024 in the DISC project’s focus geographies. The methods include several annual rounds of data collection, with 4 research methodologies: provider surveys, client exit interviews (CEIs), Household Surveys (HHS), and two follow up surveys with the individuals who participate in the CEIs.
Research Objectives
1. To understand exposure to information about self-injectable contraceptives in the DISC sentinel areas.
2. To understand knowledge and attitudes about self-injectable contraceptives among women in DISC sentinel areas.
3. To understand sexual and reproductive health empowerment among women of reproductive age and SI users in DISC sentinel areas.
4. To understand users’ experiences with self-injection training
5. To understand providers’ knowledge and attitudes regarding self-injectable contraceptive service provision.
6. To understand initiation and continuation of self-injection following training.
7. To gain lessons regarding client exit survey methodology for future survey implementation among self-inject clients.
8. To gain learnings regarding follow-up methodologies for future survey implementation among self-inject clients, particularly as relates to continuation measurement.
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|